Updates are available Correction dated 2026-08-17
Click to view Correction: https://doi.org/10.1186/s12974-026-03998-7
-
Authors
Farr, Susan A.
Cuzzocrea, Salvatore
Esposito, Emanuela
Campolo, Michela
Niehoff, Michael L.
Doyle, Timothy M.
Salvemini, Daniela https://orcid.org/0000-0002-0612-4448
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (1R01NS111120-01A1)
National Institute of Neurological Disorders and Stroke (1R01NS111120-01A1)
- License Information
-
More Information
Article History
Received: 24 July 2020
Accepted: 22 October 2020
First Online: 12 November 2020
Change Date: 17 August 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12974-026-03998-7
Ethics
Ethics approval and consent to participate: Animal care and experiments were performed in agreement with Italian regulations on protection of animals used for experimental purposes (Ministerial Decree 16192), the Council Regulation (EEC) (Official Journal of the European Union L 358/1 12/18/1986) and the National Institutes of Health NIH Guide for Care and Use of Laboratory Animals (USA). All procedures were approved by The University of Messina Review Board for the Care of Animals and Saint Louis University Institutional Animal Care and Use Committee.
Consent for publication: Not applicable.
Competing interests: Daniela Salvemini and Susan Farr have a patent (“Treatment of Alzheimer’s Disease” filed 02/25/2020, Serial No. PCT/US2020/019756) covering the intellectual property described in this manuscript. Daniela Salvemini is a founder of BioIntervene, Inc. which has licensed related intellectual property from Saint Louis University and the National Institute of Health. All other authors declare no competing interests.
